US Executive Compensation Proxy SEC Filings — February 03, 2026

CEO comp rose 25% YoY to $4.8M, 60% performance-based linked to 2026 EBITDA target of $55M (up 15% YoY), aligning mgmt with growth

EBITDA margins expanded 120 bps YoY to 18.5% on QoQ revenue growth of 5.2%, outperforming healthcare peers avg +50 bps

No insider sales in last 6 months, 3 directors pledged 150K shares (15% of holdings) post-Q3, signaling conviction ahead of merger vote

Guidance raised for 2026 revenue to $320M (+20% YoY from $267M 2025 est.), driven by merger synergies projected at $25M annual savings

ROE improved to 12% YoY from 9%, Debt-to-Equity stable at 0.8x vs sector 1.2x, supporting capital efficiency

Operational volumes up 8% YoY (home oxygen units), cost per patient down 10% QoQ, bolstering margin resilience

Shareholder approval odds 85% for merger per proxy vote simulations, unlocking 25% EPS accretion post-close

Dividend suspension continued (0% payout ratio), full reinvestment into capacity expansion targeting 15% volume growth 2026

CEO-to-median employee pay ratio declined to 45:1 from 52:1 YoY, improving governance perception

Mixed sentiment (55% bullish) on comp due to merger incentives, but TSR-linked bonuses beat threshold by 150%

Buyback authorization increased 20% to $15M (5% of market cap), first since 2024 amid undervaluation

CEO pay up 25% YoY despite revenue flat at 1.2% YoY, raising pay-for-performance misalignment concerns

Golden parachutes total $12M (3.2x base for top 5 execs), 40% above peer avg, potential shareholder revolt

4 execs pledged 25% of holdings (total 450K shares) in last quarter, possible liquidity needs amid merger uncertainty

Gross margins dipped 30 bps QoQ to 42%, 3rd consecutive quarter of pressure from supply costs up 7% YoY

2026 EBITDA target $55M assumes 12% revenue growth, but YoY miss risk if merger delays (close targeted Q2 2026)

2 shareholder proposals on comp clawbacks received 25% support, signaling dissatisfaction

Debt-to-Equity at 0.8x but up from 0.6x YoY, with $150M term loan tied to merger covenants

Mixed (45% bearish tilt) on proxy due to high fixed comp portion (40% vs peer 30%), eroding trust

Proxy vote Feb 15, 2026 offers 25% upside if approved, trading at 6x 2026 EV/EBITDA vs sector 10x

Beat potential on $55M 2026 target (mgmt confidence via comp incentives), volumes +15% forecast

Monitor post-pledge buys; current holdings 65% insider-owned, up 5% YoY

Capacity utilization to 90% in 2026 (from 82% YoY), +200 bps margin upside vs guidance

$15M program at current 4.5x EV/EBITDA supports 10-15% share accretion

Declining CEO pay ratio to 45:1 positions for ESG fund inflows, +5% institutional ownership potential

Merger $25M cost savings (8% of opex) undervalued, post-close re-rating to 9x EBITDA

Home medical volumes +8% YoY, tailwind from aging demographics for 20% CAGR

Healthcare proxies show +20% YoY exec pay avg (Quipt +25%), tied to synergies; implies M&A wave but governance risks [Healthcare]

60% avg comp now variable (Quipt 60%), linked to EBITDA/TSR; bullish for aligned mgmt but high bar for 2026 targets [Healthcare Services]

+120 bps YoY EBITDA margins (Quipt) but QoQ dips signal cost inflation; sector avg +80 bps, favoring efficient operators [Home Medical]

No sales but pledges up 20% (Quipt 25% holdings), pattern in small-cap healthcare indicates liquidity caution pre-events [Healthcare]

0% payout (Quipt), sector trend to fund growth/capex; ROE +3% avg YoY supports long equity returns [Med Devices]

Shareholder proposals avg 20% support on comp (Quipt 25%), pressuring pay ratios down 10% YoY sector-wide [Healthcare]

Shareholder meeting Feb 15, 2026; watch approval >80% for deal close Q2, potential 20% stock pop [Feb 15, 2026]

Q4 2025 results Jan 10, 2026; monitor EBITDA beat vs $12M est, merger update [Jan 10, 2026]

Track Form 4s post-proxy; any buys amid pledges signal stronger conviction [Ongoing Q1 2026]

Quarterly ops metrics vs $55M 2026 target; QoQ volume trends for margin guide [Mar 31, 2026]

$15M authorization start date post-merger; pace vs 5% float retirement [Q2 2026]

Annual comp disclosure May 2026 DEF 14A; watch if <45:1 sustains governance premium [May 2026]

Test post-Q1 2026 on 0.8x leverage; merger delay risk to compliance [Apr 2026]